GPT and metabolic dysfunction-associated steatotic liver disease: Furthermore, in a recent placebo-controlled clinical trial,32 treatment of patients with non-alcoholic fatty liver disease (NAFLD) with norUDCA resulted in a dose-dependent reduction of serum alanine aminotransferase (ALT) within 12 weeks, suggesting efficacy in human NAFLD.